COLUMN GROUP III GP, LP

10% owner sells all 4,170,266 shares of TNYA for $2.4M (blended $0.57) as stock down 71% from 52-week high, unprofitable company.

COLUMN GROUP III GP, LP, a 10% owner, executed 4 separate sales on 2026-02-24 and 2026-02-25, selling 4,170,266 shares totaling $2,380,189.07 at prices ranging from $0.56 to $0.62, liquidating its entire position. The transaction occurs as Tenaya Therapeutics stock trades 71.0% below its 52-week high of $2.10 and has declined 56.4% over the prior 90 days, while the company reported net income of $-20,275,000.00 ($-20.3M) over its most recent full fiscal year. The complete divestiture by a major shareholder coincides with significant share price deterioration and ongoing unprofitability, which constitutes a notable capital event for investors monitoring shareholder conviction and cash position changes at this early-stage therapeutics company.

10% owner COLUMN GROUP III GP, LP sells 4.40M shares (62.4% of holdings) for $3.0M at $0.69–$0.82

COLUMN GROUP III GP, LP, a 10% owner of Tenaya Therapeutics, executed 4 separate sales on 2026-02-10 and 2026-02-11, liquidating 4,400,290 shares for $3,042,222.34 at prices ranging from $0.68 to $0.82. This represents a reduction of 62.4% of the insider's pre-transaction holdings (from 7,052,107 shares to 2,651,817 shares), constituting a material reduction of a significant stake. The timing of the sales coincides with Tenaya trading at $0.68 current price, down 67.6% from its 52-week high of $2.10 and down 48.9% over 90 days, while the company reported negative net income of $-20,275,000.00 for its most recent full fiscal year. The insider's cross-ticker track record shows 20 prior purchases with an average 90-day return of +35.6%, suggesting a pattern of open-market acquisitiveness historically; this large, multi-day liquidation of a major block stands in contrast to that historical buy orientation and warrants examination of whether capital or strategic pressures drove the exit.

10% owner COLUMN GROUP III GP, LP purchases 32,507 shares across 6 transactions for $641.6K at blended $19.74; stock now $17.98

COLUMN GROUP III GP, LP executed 6 separate purchases totaling 32,507 shares for $641,597.27 between January 15–20, 2026, at prices ranging from $19.60–$20.00, lifting holdings from 984,151 to 1,016,658 shares. The blended average price of $19.74 now sits 26.9% above the current price of $17.98, reflecting a post-transaction decline of 17.4% over 30 days. The company remains unprofitable with negative net income of $-71,643,000.00 on minimal quarterly revenue of $983,000.00, limiting the transaction's interpretive clarity regarding operational confidence. This series of purchases by the 10% owner represents material position accumulation in an early-stage, cash-flow-negative biotech context, but the subsequent price deterioration and absence of measurable outcomes from the insider's prior same-ticker trades (all filed within the prior week) prevents clear pattern assessment at this stage.

10% owner COLUMN GROUP III GP, LP buys 18.0K shares for $357.4K at $19.86 avg, adding 1.8% to holdings

COLUMN GROUP III GP, LP executed 4 separate purchases totaling 17,993 shares for $357,352.51 on January 13–14, 2026, at an average price of $19.86, increasing total holdings from 981.4K to 999.4K shares (+1.8%). The transactions occurred when SRZN traded near the $20.00 current level and within a 52-week range of $6.50–$24.59, roughly -18.7% from the 52-week high. Across this insider's cross-ticker open-market history, the track record shows 0.00% 90-day win rate with an average 90-day return of -23.6%, suggesting prior trades at other companies have not timed market recoveries well. At SRZN specifically, the insider has completed 5 prior trades, with the earliest measurable outcome (December 2025 purchase) showing a +10.3% 30-day return, though 90-day outcomes remain open. The company is unprofitable (net income of $-71.6M for the most recent full fiscal year) with minimal quarterly revenue ($983.0K), and the market cap stands at $171.4M.

COLUMN GROUP III GP LP (10% owner) bought 15,100 shares at $19.89 on 2026-01-06 for $300,296.72

COLUMN GROUP III GP LP executed 2 separate purchases totaling 15,100 shares for $300,296.72 at a blended average price of $19.89, increasing its stake from 974,793 to 989,893 shares (+1.5%). The purchase occurred at $19.89 per share versus a current price of $19.06 (−0.9% from transaction), well below the 52-week high of $24.59 (−19.1% decline). Notably, this insider accumulated shares during a sharp 30-day decline of −13.8% and immediately after executing 2 prior purchases on 2025-12-05 and 2025-12-04 at SRZN, a pattern of sustained accumulation across a compressed timeframe. However, this company is unprofitable with quarterly revenue of $983,000.00 and a full-year net loss of $-71,643,000.00, creating fundamental headwinds. The insider's cross-ticker track record shows 0% of prior buys achieved positive 90-day returns (avg −23.6%), though same-ticker purchases over the prior month have posted strong 30-day gains (+94.4%, +24.2%, +24.2%, +10.3%, +10.3%), and 90-day outcomes remain unmeasurable on these recent trades.

COLUMN GROUP III GP, LP (10% owner) bought 36,150 shares across 4 transactions for $694,850.46, raising stake to 981,890 shares

COLUMN GROUP III GP, LP executed 4 separate purchases totaling 36,150 shares for $694,850.46 on 2025-12-04 and 2025-12-05, at a blended average price of $19.22, increasing holdings by 3.8% to 981,890 shares. The stock has appreciated 0.0% from its 52-week high of $20.47 and is up 67.8% over 30 days and 74.9% over 90 days, trading near the top of its annual range. However, the insider's timing track record at this ticker is poor: in 3 prior measurable purchases at SRZN (all from March 2025), the stock declined an average 23.4% within 90 days, and 0 of 3 prior buys were well-timed. The company remains unprofitable with a net income of $-71,643,000.00 against quarterly revenue of $983,000.00, and the insider's broader cross-ticker buy history shows negative average returns of -17.2% (30-day) and -23.6% (90-day) with a 0.00% win rate across 9 prior purchases.

10% owner COLUMN GROUP III GP, LP buys 315,457 shares at $12.65 in 2 transactions ($4.0M), raising stake 48.7%

COLUMN GROUP III GP, LP, a significant 10% stakeholder in Surrozen, Inc., executed 2 separate open-market purchases totaling 315,457 shares (315.5K shares) for $3,990,531.05 ($4.0M) on 2025-11-13 at a blended average price of $12.65, increasing holdings by 48.7% from 647,261 shares to 962,718 shares. This represents a material accumulation event at current price of $12.80, positioned 24.8% below the 52-week high of $17.02, amid a 30-day decline of 5.7% and 90-day gain of 14.8%. Critically, this insider's prior trades at SRZN show a 0% win rate at the 90-day mark (none of 5 prior buys were well-timed), with those prior March 2025 and April 2024 purchases both declining significantly. The company's fundamentals remain challenged, with latest quarter revenue of $983,000.00 ($983.0K), net income of $-71,643,000.00 ($-71.6M), and a market cap of $109,714,188.80 ($109.7M), reflecting ongoing unprofitability. The purchase pattern and unfavorable historical timing record at this ticker warrant investor attention.

COLUMN GROUP III GP buys 1,034,482 shares at $11.60 for $12.0M despite prior buys at this ticker posting -35.5% and -29.1% returns.

COLUMN GROUP III GP, a 10% owner, executed 3 separate purchases totaling 1,034,482 shares at $11.60 for $11,999,991.20 on 2025-03-26. The transaction is noteworthy in the context of the insider's historical trade execution: prior buys at Surrozen on 2024-04-04 each returned -35.5% over 30 days and -29.1% over 90 days, with a cross-ticker track record showing 0 of 4 prior buys well-timed at the 90-day mark (avg 90d return: -21.6%). The company's fundamentals show annual revenue growth of -100.0%, unprofitability (net income: $-1.4M in latest quarter), and a $35.8M market cap. The current stock price of $11.01 is -35.3% from the 52-week high of $17.02 and has declined 7.7% over 30 days and 20.8% over 90 days. This large accumulation by a major shareholder arrives during sustained price weakness and follows a documented pattern of poorly-timed prior entries at the same ticker.

10% owner COLUMN GROUP III GP, LP purchases 35,714,284 shares at $0.70, boosting stake to 49.31M; stock now -93.2% from 52-week high.

COLUMN GROUP III GP, LP increased its stake in Tenaya Therapeutics by 262.6%, purchasing 35,714,284 shares for $24,999,998.80 on 2025-03-05 at $0.70 per share. The company currently trades at $0.46 (down 55.8% in 30 days and 87.2% in 90 days), representing a 93.2% decline from its 52-week high of $6.80. Across the insider's cross-ticker open-market history, prior buys averaged -16.9% 30-day return and -21.6% 90-day return with a 0% win rate; at this specific ticker, the insider's prior buy on 2024-02-12 saw a -6.7% 90-day return. Against this backdrop of persistent unfavorable timing patterns and a company posting net losses of $25,634,000 with a market capitalization of only $36,441,437.36, the decision to deploy $25M in additional capital requires investor scrutiny regarding the insider's conviction thesis and access to information not yet public.